Weaver C. Barksdale & Associates’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.32M Sell
5,202
-10
-0.2% -$2.33K 1.19% 52
2026
Q1
$1.27M Sell
5,212
-171
-3% -$39.8K 1.21% 50
2025
Q4
$1.12M Sell
5,383
-1,052
-16% -$208K 1.17% 48
2025
Q3
$1.19M Sell
6,435
-606
-9% -$104K 1.15% 47
2025
Q2
$1.08M Sell
7,041
-87
-1% -$13.4K 1.03% 54
2025
Q1
$1.18M Sell
7,128
-240
-3% -$37.6K 1.13% 53
2024
Q4
$1.07M Sell
7,368
-260
-3% -$40.3K 1.02% 56
2024
Q3
$1.24M Sell
7,628
-405
-5% -$64.5K 1.11% 52
2024
Q2
$1.17M Sell
8,033
-186
-2% -$27.7K 1.11% 50
2024
Q1
$1.3M Sell
8,219
-87
-1% -$13.8K 1.19% 51
2023
Q4
$1.3M Sell
8,306
-2,285
-22% -$350K 1.27% 48
2023
Q3
$1.65M Buy
10,591
+555
+6% +$91.6K 1.41% 44
2023
Q2
$1.66M Sell
10,036
-740
-7% -$119K 1.64% 40
2023
Q1
$1.67M Buy
10,776
+1,596
+17% +$258K 1.56% 40
2022
Q4
$1.62M Buy
9,180
+259
+3% +$44.7K 1.43% 46
2022
Q3
$1.46M Sell
8,921
-353
-4% -$59.7K 1.46% 44
2022
Q2
$1.65M Buy
9,274
+85
+0.9% +$15.1K 1.53% 41
2022
Q1
$1.63M Buy
9,189
+128
+1% +$21.8K 1.45% 45
2021
Q4
$1.55M Buy
+9,061
New +$1.48M 1.4% 50
2017
Q4
$1.59M Sell
11,405
-153
-1% -$21.3K 1.68% 22
2017
Q3
$1.5M Hold
11,558
1.68% 20
2017
Q2
$1.53M Hold
11,558
1.78% 9
2017
Q1
$1.44M Buy
11,558
+2,709
+31% +$324K 1.7% 17
2016
Q4
$1.02M Sell
8,849
-50
-0.6% -$5.78K 1.64% 12
2016
Q3
$1.05M Buy
8,899
+199
+2% +$24.1K 1.77% 3
2016
Q2
$1.05M Hold
8,700
1.83% 8
2016
Q1
$941K Sell
8,700
-58
-0.7% -$6K 0.71% 42
2015
Q4
$900K Hold
8,758
0.7% 41
2015
Q3
$818K Hold
8,758
0.66% 46
2015
Q2
$854K Buy
8,758
+1,013
+13% +$101K 0.63% 49
2015
Q1
$779K Hold
7,745
0.59% 63
2014
Q4
$810K Sell
7,745
-131
-2% -$13.8K 0.65% 57
2014
Q3
$840K Hold
7,876
0.69% 38
2014
Q2
$824K Hold
7,876
0.66% 43
2014
Q1
$774K Hold
7,876
0.65% 47
2013
Q4
$721K Buy
7,876
+30
+0.4% +$2.77K 0.61% 56
2013
Q3
$680K Buy
7,846
+3,885
+98% +$349K 0.62% 44
2013
Q2
$340K Buy
+3,961
New +$336K 0.33% 68

Other funds holding JNJ

Weaver C. Barksdale & Associates's JNJ Position: Q2 2026 in Review

Weaver C. Barksdale & Associates reduced its Johnson & Johnson (JNJ) stake by 0.19% in Q2 2026, selling an estimated $2.33K and leaving 5,202 shares worth $1.32M. The position accounts for 1.19% of the portfolio, ranked #52.

Weaver C. Barksdale & Associates first reported a position in JNJ in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.67M in Q1 2023. 4,665 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Weaver C. Barksdale & Associates held 5,202 shares of Johnson & Johnson worth $1.32M as of Q2 2026.
  • Weaver C. Barksdale & Associates sold 10 Johnson & Johnson shares in Q2 2026, an estimated $2.33K.
  • Johnson & Johnson made up 1.19% of Weaver C. Barksdale & Associates's portfolio in Q2 2026, its #52 holding.
  • Weaver C. Barksdale & Associates first reported a position in Johnson & Johnson in Q2 2013 and has held it in 38 quarters since.
  • Weaver C. Barksdale & Associates's Johnson & Johnson position peaked at $1.67M in Q1 2023.
  • 4,665 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.